Deep integration of proven AI tools into Philips cardiovascular ultrasound systems to better diagnose more cardiac disease patients
04 Juin 2024 - 3:00PM
Deep integration of proven AI tools into Philips cardiovascular
ultrasound systems to better diagnose more cardiac disease patients
June 4, 2024
- New FDA-cleared AI-enabled applications include the industry’s
first automated tool for segmental wall motion scoring of the heart
to quickly and objectively identify disorders including coronary
artery disease and cardio-oncology issues in seconds
- First fully automated 3D quantification of mitral regurgitation
(MR) volumes* designed to provide reproducible, efficient analysis
helps clinicians make better-informed decisions for patients with
heart valve disease
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology,
announced its next-generation AI-enabled cardiovascular ultrasound
platform to help speed up cardiac ultrasound analysis with proven
AI technology and reduce the burden on echocardiography labs.
Integrated into the company’s EPIQ CVx and Affiniti CVx ultrasound
systems, the new FDA 510(k) cleared AI applications significantly
advance Philips’ cardiovascular imaging and diagnosis solutions,
automating measurements and speeding workflows to increase
productivity.
Heart failure is a rapidly growing health issue that affects an
estimated 64 million people worldwide [1]. It's also
associated with high mortality and poor quality of life, and is a
substantial burden on healthcare systems globally [2]. As the most
common and least invasive way to check the structure and function
of the heart, cardiovascular ultrasound has played a key role in
diagnosing cardiac disease earlier.
“As clinical cases get more complex and patient volumes
increase, we read hundreds of echocardiography exams daily with
thousands of data points,” said Roberto Lang, MD, Director of the
Noninvasive Cardiac Imaging Lab, University of Chicago Medicine,
USA. “With the integration of AI into echocardiography solutions,
we can now automate some of the steps to support clinicians'
decision-making, allowing them to detect, diagnose, and monitor
various cardiac conditions with greater confidence and efficiency
in seconds.”
Dr. Lang will join other clinicians to share the results of a
new scientific abstract being presented at the American Society of
Echocardiography (ASE2024) annual meeting (June 14 – 16, Portland,
US), demonstrating how first-of-kind AI algorithms co-developed
with Philips provide highly accurate detection of regional wall
motion abnormalities (RWMA) on echocardiography. RWMAs
can be an independent indicator of adverse cardiovascular events
and death in patients with cardiovascular diseases
like myocardial infarction (MI) and congenital heart
disease. Automated machine learning-based assessment of RWMA has
the potential to improve the efficiency of all readers. “An
advantage of AI methods over conventional visual analysis is that
it can be performed in seconds, providing rapid and accurate
information to help augment expert reads by quickly highlighting
areas of concern for RWMA, improving the ease and efficiency of
interpretation,” Lang added.
“By harnessing the power of AI into our echocardiography
solutions, we empower clinicians with enhanced diagnostic
capabilities, to ultimately improve patient care and outcomes in
the management of coronary and valvular disease, while enhancing
overall efficiency in cardiac practice,” said David Handler, VP and
Business Leader for Global Cardiovascular Ultrasound at Philips.
“For patients, this means consistent image interpretation which can
lead to fewer re-scans, shorter and more effective interventional
procedures, and potentially faster recovery times.”
Integration of proven AI applications from Philips DiA
Imaging Analysis Trained on anonymized patient data sets
from real-life clinical environments, the AI features integrated
across Philips cardiovascular ultrasound systems help improve the
quality and reproducibility of cardiac imaging and enhance operator
and departmental efficiency. These include FDA-cleared and
CE-marked software solutions from DiA Imaging Analysis, a Philips
company. Together, these AI features automate how users interpret
ultrasound images, so clinicians with varying levels of ultrasound
experience can automatically analyze images with increased speed,
efficiency, and accuracy in real time.
In addition to integrating these latest advanced AI features
into the company’s cardiovascular ultrasound systems, Philips’ new
mini ultrasound transducer X11 4t, introduced earlier this year, is
fully compatible with the EPIQ CVx and Affiniti CVx systems. The
innovative transducer allows interventional cardiologists to
provide enhanced care to a wider range of patients, including
pediatric patients as small as 5kg in weight.
Through breakthrough innovation and collaborations with
technology leaders including NVIDIA**, Philips continues to rapidly
integrate AI into its cardiovascular ultrasound portfolio to help
improve efficiency and productivity and mitigate staff shortages
while delivering high-quality cardiology care to an increasing
number of patients. These third-party solutions complement Philips’
proprietary AI-enabled solutions, integrating AI to enhance
diagnostic confidence and decision-making.
For more information, join Philips in Booth #441 at ASE2024 and
visit Philips Cardiovascular Ultrasound for the latest AI-powered
echocardiography applications.
*Clinical performance and safety have not been established for
some features which have 510(k) pending. Not available for sale in
the USA.**NVIDIA MONAI for medical imaging AI and NVIDIA Holoscan
for building software-defined medical devices.
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398425/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398425/
For further information, please contact:
Kathy O’ReillyPhilips Global External RelationsTel.: +1 978 221
8919E-mail : kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring,
and enterprise informatics, as well as in personal health. Philips
generated 2023 sales of EUR 18.2 billion and employs approximately
69,100 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
- Using AI technology to enhance assessment of heart function
through cardiac ultrasound image analysis
- Using AI technology for automated evaluation of heart function
through segmental wall motion scoring
- Clinical image showing how integrating AI into cardiac
ultrasound provides automated segmental wall motion scoring
- Clinical image showing cardiac ultrasound display for image
analysis enhanced through integration of AI.
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024